Announcements

Marcella Nunez-Smith, MD, MHS, Appointed Director of the Center for Community Engagement and Health Equity

I am delighted to announce the appointment of Marcella Nunez-Smith, MD, MHS, as Director of the Center for Community Engagement and Health Equity within Yale Cancer Center and Smilow Cancer Hospital, as well as Chief Health Equity Officer and Deputy Chief Medical Officer at Smilow Cancer Hospital, and Associate Cancer Center Director for Community Outreach and Engagement at Yale Cancer Center. Dr. Nunez-Smith's accomplished leadership since joining the faculty at Yale in 2006, innovative ideas for expanding our positive impact in our communities, and passionate and determined values will propel our efforts to improve our understanding of and reduce health disparities relevant to cancer care.

In her new role, Dr. Nunez-Smith will unify all of the accomplished work in community engagement and health equity across Yale School of Medicine, Yale School of Public Health, Yale Cancer Center, and Smilow Cancer Hospital by developing an umbrella infrastructure, The Bridge Center. The Bridge Center will...
guide and support partnerships within and beyond the University to reach and sustain our goals for health equity. In addition, the newly defined Center will oversee several approaches to community-engaged research, community outreach, education, policy & advocacy, and access to clinical care, including Community Engagement; Cancer Screening; and Clinical Research with the continued Cancer Center leadership of Beth Jones, PhD, MPH, Xavier Llor, MD, PhD, and Andrea Silber, MD.

**Markus Müschen, MD, PhD, Named Director of the Center of Molecular and Cellular Oncology**

I am very pleased to announce Markus Müschen, MD, PhD, as the inaugural Director of the Center of Molecular and Cellular Oncology at Yale Cancer Center and Smilow Cancer Hospital. Dr. Müschen is an innovative and highly productive physician-scientist. His leadership experience and mentorship will be a tremendous asset for Yale Cancer Center as we continue to expand our efforts in cancer research and hematological malignancies.

He joins Yale from City of Hope Comprehensive Cancer Center where he currently is the Associate Director of Basic Science and Professor and Chair of the Department of Systems Biology. Dr. Müschen is a Howard Hughes Medical Institute Faculty Scholar, a National Cancer Institute Outstanding Investigator Award (R35) recipient, and formerly a scholar of the Leukemia & Lymphoma Society, a senior investigator of the Wellcome Trust at the University of Cambridge (U.K.), and the Sir Alexander Haddow Professor of the Institute for Cancer Research in London.
Yale Cancer Center researchers were awarded a $11 million grant renewal from the NIH to fund the Yale Specialized Programs of Research Excellence (SPORE) in Lung Cancer. The goal of the Yale SPORE in Lung Cancer is to reduce mortality through the development of novel therapeutics and treatment approaches by quickly bringing research advances in tumor development, therapeutic resistance, and development of metastasis from the laboratory to patients with lung cancer.

"The support of the SPORE in Lung Cancer creates critical collaborations between basic, translational, and clinical scientists and helps shepherd advances from our labs to benefit all patients with lung cancer," said principal investigator Roy S. Herbst, MD, PhD, Ensign Professor of Medicine, Chief of Medical Oncology, and Associate Cancer Center Director for Translational Research.

The SPORE in Lung Cancer will focus on three primary projects during the next funding period. The first project will analyze the immune suppressor capabilities of Siglec-15 and the potential success of the Siglec-15 inhibition patients with lung cancer with the development of predictive biomarkers (Drs. Lieping Chen, David Rimm, and Scott Gettigner). A second project will evaluate approaches to prevent tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer (Drs. Katerina Politi, Sarah Goldberg, and Mark Lemmon). The third project in the SPORE in Lung Cancer will target lung...
cancer metastasis and drug resistance in the central nervous system (Drs. Don Nguyen, Abhijit Patel, and Anne Chiang).

Learn More >>

Thuy Tran, MD, Appointed to Medical Oncology

I am pleased to announce that Thuy Tran, MD, was recently named an Instructor of Medicine (Medical Oncology). Dr. Tran cares for patients with melanoma, prostate, and genitourinary cancers at Smilow Cancer Hospital in New Haven and at the West Haven Veterans Administration Hospital Cancer Center. She completed her residency in Internal Medicine at Yale New Haven Hospital and participated in the ABIM Physician-Scientist Research Pathway. Dr. Tran received her medical degree from Vanderbilt University School of Medicine.

This year, Dr. Tran received funding through the YCC K12 Calabresi Immuno-Oncology Training Program to support her research into anti-PD-1 and anti-VEGFR in brain metastases. In 2019, she received a five-year grant through the Yale Cancer Center-Advanced Training Program for Physician-scientists (YCC-ATPP) for her project Models of Melanoma Brain Metastasis-Associated Vasogenic Edema and Development of Novel Anti-Edema Therapies.

Smilow Cancer Hospital and Yale Cancer Center are proud to be part of the Sarcoma Alliance for Research Collaboration (SARC), a collaboration of distinguished research institutions throughout the country, which pool their expertise to design, perform, and evaluate clinical trials, with the ultimate goal of ending sarcoma. Thanks to the leadership of Dr. Hari Deshpande, Associate Professor of Medicine (Medical Oncology), Smilow Cancer Hospital and Yale Cancer Center have been a member institution of this prestigious group since 2016.

Smilow Cancer Hospital and Yale Cancer Center is a member institution of the prestigious Sarcoma Alliance for Research through Collaboration (SARC).

Read More >>
Dr. Alexander Pine Appointed to Hematology

Alexander Pine, MD, PhD, recently completed the Yale Medical Oncology-Hematology Fellowship Program and has joined Smilow Cancer Hospital as an Assistant Professor of Medicine (Hematology). Primarily, he cares for patients with hematologic disorders at the West Haven Veterans Administration Hospital Cancer Center. Dr. Pine completed his residency in Internal Medicine at Yale New Haven Hospital, received his medical degree from Case Western Reserve University School of Medicine, and his PhD from Drexel University.

Dr. Pine will focus on clinical and research bioinformatics in hematology and is committed to advancing the understanding of factors that impact clinical outcomes of patients with disorders of thrombosis and hemostasis, and translating that data to improve outcomes. He will be working closely with Drs. Amy Justice and Alfred Lee, seeking to identify new treatment targets for patients with thrombotic and hemostatic disorders.

Notables

Jill Lacy, MD, Professor of Medicine (Medical Oncology) received the 2020 Rosemarie L. Fisher, MD Award for Excellence in Graduate Medical Education. The annual award recognizes extraordinary accomplishment in Graduate Medical Education and is granted to a member of the Graduate Medical Education Community of Yale New Haven Hospital and Yale School who has made substantial contributions to advance the training of residents and fellows. The award was established in 2017 and Dr. Lacy is the fourth recipient of the honor.

David Madoff, MD, Professor of Radiology and Biomedical Imaging, has assumed the role

Dr. Aron Flagg will discuss the latest options for Pediatric Lymphoblastic Leukemia on Yale Cancer Answers. Tune in to Connecticut Public Radio or download our podcast from iTunes.

A huge thank you to Maggie Carley, a local high school student, who rallied her peers to provide meals to our team at the Smilow Cancer Hospital Care Center in Trumbull. Maggie reached out to her peers at Trumbull High School and friends through social media recommending they do chores to earn money to help others. Through the initiative, she was able to raise $1000 and solicited additional support from Crown Pizza, located on Main Street in Trumbull. Thank you, Maggie, for the amazing lunch for our team and for your inspiring
of Interventional Radiology Section Chief and leader of the Interventional Oncology Program for Smilow Cancer Hospital. David, who is also Vice Chair for Clinical Research and Co-Chair of the Interventional Oncology Research Lab was division chief and vice chair for academic affairs at Cornell before being recruited to Yale in 2019. David will also collaborate closely with the HVC service line to develop quality IR services across the System.

Smilow Cancer Hospital and Yale Cancer Center leadership are grateful to Kevin Kim, MD, MHS, for his tireless efforts as section chief over the past 4 years as he built an outstanding Interventional Oncology Program and we look forward to continuing our collaborations and excellence in clinical care together.

Congratulations to the following faculty who were recently approved for promotion:

- Ranjit Bindra, MD, PhD, Professor of Therapeutic Radiology
- Benjamin Judson, MD, Professor of Surgery (Otolaryngology)
- Sarah Mougalian, MD, Associate Professor of Medicine (Medical Oncology)
- Stuart Seropian, MD, Professor of Medicine (Hematology)

Kurt Schalper, MD, PhD, Assistant Professor of Pathology and Medicine (Medical Oncology) received an R37 Merit Award from the National Institutes of Health (NIH) to fund his research in pathways for cancer immunotherapy over the next 7 years.

The Association of American Cancer Institutes (AACI) has elected Charles Fuchs, MD, MPH, to its Board of Directors.

Lynn D. Wilson, MD, MPH, Professor of Therapeutic Radiology, is the recipient of the Anthony Edward

Get to know Dr. Johanna Lasala, Assistant Professor of Clinical Medicine (Medical Oncology) at our Smilow Cancer Hospital Care Center in Orange, and hear why she enjoys the one-on-one interactions with her patients, in this recent interview.

July is Sarcoma Awareness Month. The Sarcoma Program at Smilow Cancer Hospital includes a multidisciplinary team of physicians specialized in the diagnosis, treatment, and care of patients with both soft tissue sarcomas and sarcomas of the bone. We offer surgery, radiation, and other therapeutic options, including the latest in clinical trials, with treatment plans tailored to every individual diagnosis.
Kupka '64 Distinguished Alumnus Award from Yale, a private independent school for boys in Bethesda, Maryland. The award is presented each year to an alumnus who has demonstrated the ideals for which Landon stands through service to Landon, his community, his profession, or his country. Learn More

Sanjay Aneja, MD, Assistant Professor of Therapeutic Radiology and a member of Yale Cancer Center's Radiobiology and Radiotherapy Research Program, will present on July 13 at the National Academies workshop on Digital Health Applications in Oncology on "Applications of Deep Learning in Diagnostic Image Analysis."

Yale's COVID-19 Research Resource Fund, which was built with generous contributions from Yale's donors, has awarded funding to three pilot projects out of 44 submissions. Of the three selected projects, two are led by Yale Cancer Center scientists. Karen S. Anderson, PhD, Professor of Pharmacology and of Molecular Biophysics and Biochemistry, and William L. Jorgensen, PhD, Sterling Professor of Chemistry, will apply their complementary expertise toward developing "A Computational Approach for Discovering Novel SARS2 protease Inhibitors." "Development of a genomic toolset to expedite basic and applied research on SARS-CoV-2" is a collaboration between Brett Lindenbach, PhD, Associate Professor of Microbial Pathogenesis and of Comparative Medicine, an expert on (+)-strand RNA viruses, including several that affect human health; and Farren Isaacs, PhD, Associate Professor of Molecular, Cellular, and Developmental Biology and Biomedical Engineering at the Systems Biology Institute.

We'd like to take a moment to thank Kathleen Uscinski, Assistant Director for Clinical Trial Operations, Smilow Cancer Hospital Care Centers, for her 36 years of service to Yale University and the Yale Cancer Center Clinical Trials Office, and congratulate her on her retirement! We recently celebrated her career with a secretly-planned ZOOM celebration, featuring tributes from Yale Cancer Center and Smilow Cancer Hospital leadership and many other members of our faculty, the Yale Human Investigations Committee, colleagues from previous departments throughout Yale University (including the Privacy Office, Labor Relations, and others), and colleagues and friends from our Clinical Trials Office.

Halfway through the "Open House" Kathleen was surprised by a police-escorted car parade zooming by her home. The parade included more than 30 colleagues from her last several decades at Yale who stopped to plant signs of good wishes and deliver special gift baskets. Congratulations, Kathleen - we wish you all the best and thank you for dedication and service over the last 36 years!
The Genetics, Genomics, and Epigenetics Program welcomes Sigrid Nachtergaele, PhD, Assistant Professor of Molecular, Cellular, and Developmental Biology. In her laboratory, her team aims to expand the scope of looking at numerous, less characterized modifications in a variety of cancers. Specifically, they hope to understand how RNA modifications regulate gene expression programs, and how they become misregulated in disease, and specifically in cancer moving forward.

**Employee Profile: Pamela-Jean Berkheiser**

When it became apparent that many clinical areas would need to be relocated due to COVID-19, Pamela-Jean Berkheiser had been in her role as Administrative Director for Ambulatory Practice at Smilow Cancer Hospital for less than a year.

Overseeing front desk staff, medical assistants, clinical operations managers, and administrative staff, meant that a lot of coordination was needed to make sure her...
staff members received the resources they needed, while also working to transition patient care from the main hospital to the Smilow Care Centers, and now back again. With two of the three floors currently transitioned back to the main hospital, Pamela has focused on making sure that patients and staff remain safe. She commented that her main concern now is making sure the waiting areas are not crowded, and that requires balancing the number of patients that can be seen per hour to maintain social distancing with the number of staff and providers.

"With many staff members still working remotely, we are spread across more locations now. Our main goal is to maintain patient care, while keeping everyone safe," said Pamela. "My staff had to move very quickly to make all of this happen, and every patient had to be called to convert to Telehealth. I am so proud of all of their hard work."

During her career, Pamela has worked in practically every medical setting from private practice to the hospital setting, and has carried experiences from each with her. "We are not caregivers, but are helping patients in other ways. If we can do something to make their day better while they are going through a challenging time, I see that as my contribution. And I am certain that my staff feels the same way," said Pamela.

#OOTB Thanks

and consistent over the last several months. Thank you, Maureen!

Follow Yale Cancer Center on Twitter

We are proud to announce the renewal of our NIH grant to fund the Yale #SPORE in #LungCancer. Thanks to @DrRoyHerbstYale for his leadership & the entire team. Their collaboration will make an impact for patients w lung cancer.

@JLeBlancMD @tristenspark talked to @Vogue about their new research @JAMA_Surgery showing a higher number of women w/breastcancer were diagnosed at an early stage in states w/expanded Medicaid coverage.

Congratulations to @YaleCancer Director @CharlesFuchsMD on being appointed to the board of
Yale Cancer Center & Smilow Cancer Hospital's #OUTOFTHEBLUETHANKS recently recognized Alyssa Gateman, MPH, CCRP, Director of Quality Assurance for the Yale Center for Clinical Investigation after she recently went above and beyond to contact the right people and secure an agreement with YNHH IT on behalf of the Cancer Center so a critically important audit could be scheduled. We want to thank her for her efforts and let her see how special this was to all of us for the YCC UM-1 grant. Many thanks, Alyssa!

Yale Cancer Center and Smilow Cancer Hospital’s #OUTOFTHEBLUETHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. If you are interested in submitting a nomination, please complete this nomination form and return it to the Director’s Office c/o Anna Raso.

Recent Publications


Shah, M. A., Enzinger, P., Ko, A. H., Ocean, A. J., Philip, P. A., Thakkar, P. V., Cleveland, K., Lu, Y., Kortmansky, J., Christos, the @AACI_Cancer for a two-year term.

@GeorgeGoshuaMD discussed new research led by@YaleCancer scientists identifying a cause of #bloodclots in #COVID19 patients that may aid in treatment with @LisaCarberg @WTNH

New research in @JAMASurgery led by@JLeBlancMD @tristenspark shows #breastcancer is detected earlier in women in states in the U.S. with expanded #Medicaid coverage through the Affordable Care Act.

We are excited to announce Dr. Markus Müschen as our inaugural Director of the new Center of Molecular & Cellular #Oncology @YaleCancer @SmilowCancer to help continue to expand our efforts in #cancerresearch & #hematologic almalignancies.

Thank you to @YaleMed Dean Dr. Nancy Brown for joining us for today's@YaleCancer virtual Grand Rounds “Town Hall: State of the Yale School of Medicine.” Dr. Brown discussed many topics including new leadership appts, future plans, and #COVID19.

Encouraging research led by . @YaleCancer in the fight against #COVID19. A new study in @TheLancetHaem by @GeorgeGoshua MD Alfred Lee @hyungjchun identifies the cause of blood clotting & may aid in treatment.


Gleeson, S. E., Britto, C. J., Azmy, V., Kaman, K., Gaston, D. C., Davis, M., Burrello, T., Harris, Z., Villanueva, M. S., Aoun-Barakat, L., Kang, I., LoRusso, PM ... Malinis, M.  
**Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes.**  
*Chest*, S0012-3692(20)31670-6. Advance online publication.  
Read More >>

**Rewired signaling network in T cells expressing the chimeric antigen receptor (CAR).**  
The *EMBO journal*, e104730. Advance online publication.  
Read More >>

Singh, V., Chu, Y., Gupta, V., & Zhao, C. W.  
**A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma.**  
*Cureus*, 12(6), e8395.  
Read More >>

**Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?**  
*Radiology*, 200373. Advance online publication.  
Read More >>

Claus, E. B., Feliciano, J., Benz, L. S., & Calvocoressi, L.  
**Social media partnerships with patient organizations for neuro-oncology patient recruitment.**  
*Neuro-oncology practice*, 7(2), 143-151.  
Read More >>

Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. 
*Urologic oncology*, S1078-1439(20)30266-0. Advance online publication.
Read More >>

**IL-7 receptor alpha defines heterogeneity and signature of human effector memory CD8+ T cells in high dimensional analysis.**
*Cellular immunology*, 355, 104155. Advance online publication.
Read More >>

Gilani, S. M., Adeniran, A. J., & Cai, G.
**Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytologic Evaluation of Intraductal Papillary Mucinous Neoplasm and Mucinous Cystic Neoplasms of Pancreas.**
*American journal of clinical pathology*, aqaa079. Advance online publication.
Read More >>

Ruddle N. H.
**Basics of Inducible Lymphoid Organs.**
*Current topics in microbiology and immunology*, 10.1007/82_2020_218. Advance online publication.
Read More >>

Chiang, A. C., Sequist, L., Gilbert, J., Conkling, P., Thompson, D., Marcoux, J. P., Gettinger, S., Kowanetz, M., Molinero, L., O'Hear, C., Fassô, M., Lam, S., & Gordon, M. S.
**Clinical Activity and Safety of Atezolizumab in a Phase 1 Study of Patients With Relapsed/Refractory Small-Cell Lung Cancer.**
*Clinical lung cancer*, S1525-7304(20)30148-0. Advance online publication.
Read More >>

**Funding Opportunities**

DeLuca Pilot Award Grants
Five pilot awards will be awarded to support investigators participating in Hematology research for the purpose of establishing research collaborations between scientists/researchers at Yale and primary Hematology faculty and to generate preliminary data and evidence of collaboration for new NCI/NIH grant applications. The research should seek to advance our knowledge in hematologic disorders and to improve patient care, therapies, and outcomes.  
**Application Deadline:** July 20, 2020  
[Learn More >>](#)

### Serological Sciences Network (SeroNet) RFAs

- Research Projects in SARS-CoV-2 Serological Sciences (U01)  
- SARS-CoV-2 Serological Sciences Centers of Excellence (U54)

Funding for these RFAs was provided through Congressional appropriation enacted in response to the COVID-19 pandemic to NCI "to develop, validate, improve, and implement serological testing and associated technologies." In response, NCI intends to use this emergency appropriation in part to establish a Serological Sciences Network to which these RFAs correspond.  
**Application Deadlines:** July 22, 2020  
[Learn More >>](#)

### Breast Cancer Alliance Young Investigator Grant

To encourage a commitment to breast cancer research, Breast Cancer Alliance invites clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers, to apply for funding for the Young Investigator Grant.  
**Application Deadline:** July 24, 2020  
[Learn More >>](#)

### Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43)

The purpose of this FOA is to establish an institutional program for mentored training in global cancer research.  
**Application Deadline:** July 24, 2020  
[Learn More >>](#)

---

**Submissions**

Please submit your recent publication and grant announcements to:  

**Renee Gaudette**  
Director, Public Affairs and Communications
The St. Baldrick's Foundation-American Cancer Society Childhood Cancer Research RFA
St. Baldrick's Foundation and the ACS are collaborating to provide funding to advance innovative translational pediatric cancer research conducted within the context of a clinical trial. Studies may include analysis of clinical data and biospecimens collected from children enrolled in a clinical trial.

**Letter of Intent Due:** July 27, 2020
[Learn More >>](#)

JH Milstone Fund Grant
JH Milstone Fund will award a grant in 2020 to support early stage investigators and innovative research and education in thrombosis, thrombolysis and hemostasis.

**Application Deadline:** July 27, 2020
[Learn More >>](#)

2020 Yale Cancer Center Internal Pilot Grant Competition
These grants will support all potential areas of innovative cancer research including basic, clinical, computational, population and epidemiology, prevention/control, implementation science and translational cancer research.

**Application Deadline:** August 1, 2020
[Learn More >>](#)

DoD FY20 Kidney Cancer Research Program
The KCRP focuses on the issues regarding prevention, detection, treatment, and the long-term effects of treatment for kidney cancer for Service Members, Veterans, their families, and the American public.

**Early Career Investigator Award** - Letter of Intent Due: August 5, 2020
**Concept Award** - Letter of Intent Due: July 15, 2020
**Translational Research Partnership Award** - Letter of Intent Due: August 5, 2020
[Learn More >>](#)
Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24)
This emergency cooperative agreement FOA from the NIH provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) initiative, a consortium of community-engaged research projects to understand factors that have led to disproportionate burden of the pandemic on the underserved and/or vulnerable populations so that interventions can be implemented to decrease these disparities.
Application Deadline: August 7, 2020
Learn More >>

Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)
The purpose of this award is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers.
Application Deadline: August 8, 2020
Learn More >>

NIH Support for Conferences and Scientific Meetings (Parent R13)
The purpose of the NIH Research Conference Grant (R13) is to support high quality scientific conferences that are relevant to the NIH's mission and to the public health.
Application Deadline: August 12, 2020
Learn More >>

NCI Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during COVID-19
Current NCI funded Principal Investigators whose postdoctoral fellows have temporarily lost stipend support from a non-profit funder because of the COVID-19 global pandemic may apply for an administrative supplement to cover the postdoctoral fellow's salary plus applicable F&A for the time and effort devoted to the NCI funded grant.
Application Deadline: August 15, 2020
NCCN Pfizer Axitinib Request for Proposals (RFP)
NCCN and Pfizer are collaborating to offer a new grant opportunity seeking proposals to support NCCN Member Institution faculty utilizing axitinib. The overall aim is to develop innovative trials that will evaluate the role of axitinib in the treatment of melanoma, hepatocellular carcinoma, and colorectal cancer.
**Application Deadline:** August 12, 2020

Lasker Clinical Research Scholars Program (Si2/R00)
This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers.
**Application Deadline:** August 28, 2020

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01)
This FOA encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups.
**Application Deadline:** August 28, 2020

NCCN Pfizer Biosimilars Request for Proposals (RFP)
The intent of this RFP is to encourage NCCN Member Institutions and non-NCCN Member Institutions to submit proposals describing concepts and ideas that develop and validate enduring approaches that improve the safe and efficient adoption of biosimilars in oncology.
**Letter of Intent Due:** September 9, 2020